There are 2867 resources available
1212P - Genomic subtypes of gastric cancer associated with response to chemoradiation therapy
Presenter: Ju-seog Lee
Session: Poster session 16
1213P - DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Presenter: Samuel Klempner
Session: Poster session 16
1214P - Prognostic value of 68Ga-FAPI PET/CT in esophageal squamous cell carcinoma: A pilot study
Presenter: Liang Zhao
Session: Poster session 16
1215P - Neoadjuvant concurrent chemoradiotherapy combined with immunotherapy in the treatment of adenocarcinoma of the oesophagogastric junction: A phase II study
Presenter: Rongxu Du
Session: Poster session 16
1216P - Prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma under HER2 blockade and immune checkpoint therapy
Presenter: Lisa Paschold
Session: Poster session 16
1217P - Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
Presenter: Hirokazu Shoji
Session: Poster session 16
1218P - Long-term survivorship rates among chemotherapy refractory or intolerant advanced esophageal squamous cell carcinoma (aESCC) patients treated with nivolumab (NIVO)
Presenter: Jaffer Ajani
Session: Poster session 16
1219P - Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
Presenter: Myriam Chalabi
Session: Poster session 16
1221P - Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6
Presenter: Zev Wainberg
Session: Poster session 16